- Human pathology

Home > A. Molecular pathology > Targeted therapy > Therapeutical antibodies > durvalumab


Thursday 9 June 2016



Durvalumab is one of PD-L1 inhibitors . It ismonoclonal antibody being investigated for the treatment of cancer. It targets programmed death ligand-1 (PD-L1), developed by MedImmune.

Clinical trials

- non-small cell lung cancer (NSCLC)

  • - trial combining durvalumab and gefitinib in NSCLC

- advanced metastatic urothelial bladder

See also

- PD-L1 inhibitors
- immune checkpoint